



CLAIMS

1. An combination comprising:
(A) antibody-recruiting molecule (ARM), and
(B) a plurality of natural killer cells;
wherein the ARM comprises:
(1) an antibody binding moiety of the formula:



; or

(2) an antibody-recruiting molecule (ARM) of formula I:




I

or a pharmaceutically acceptable salt thereof, wherein:

(a) the ABT is an antibody binding moiety that can bind to one or more antibodies, or fragments thereof;


(b) the TBT is a target-binding moiety that is;



; and

(c) L is a linker moiety that connects the ABT with the TBT;

(i) wherein the ABT is a group of the formula



or R^c-(Xaa)_z-, wherein:

each Xaa is independently an amino acid residue;

t is 0-50;

z is 1-50;

each R^c is independently -L^a-R';

each L^a is independently a covalent bond, or an optionally substituted bivalent group selected C₁-C₂₀ aliphatic or C₁-C₂₀ heteroaliphatic having 1-5 heteroatoms, wherein one or more methylene units of the group are optionally and independently replaced with -C(R')₂-, -Cy-, -O-, -S-, -S-S-, -N(R')-, -C(O)-, -C(S)-, -C(NR')-, -C(O)N(R')-, -N(R')C(O)N(R')-, -N(R')C(O)O-, -S(O)-, -S(O)₂-, -S(O)₂N(R')-, -C(O)S-, or -C(O)O-;

each -Cy- is independently an optionally substituted bivalent group selected from a C₃₋₂₀ cycloaliphatic ring, a C₆₋₂₀ aryl ring, a 5-20 membered heteroaryl ring having 1-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus and silicon, and a

3-20 membered heterocyclyl ring having 1-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus and silicon;

each R' is independently -R, -C(O)R, -CO₂R, or -SO₂R;

each R is independently -H, or an optionally substituted group selected from C₁₋₃₀ aliphatic, C₁₋₃₀ heteroaliphatic having 1-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus and silicon, C₆₋₃₀ aryl, C₆₋₃₀ arylaliphatic, C₆₋₃₀ arylheteroaliphatic having 1-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus and silicon, 5-30 membered heteroaryl having 1-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus and silicon, and 3-30 membered heterocyclyl having 1-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus and silicon, or

two R groups are optionally and independently taken together to form a covalent bond, or:

two or more R groups on the same atom are optionally and independently taken together with the atom to form an optionally substituted, 3-30 membered, monocyclic, bicyclic or polycyclic ring having, in addition to the atom, 0-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus and silicon; or

two or more R groups on two or more atoms are optionally and independently taken together with their intervening atoms to form an optionally substituted, 3-30 membered, monocyclic, bicyclic or polycyclic ring having, in addition to the intervening atoms, 0-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus and silicon; or

The diagram shows a chemical structure of a macrocyclic compound. It features a central nitrogen atom (N) bonded to four groups: R³, R^{3'}, R⁴, and a chain consisting of L¹, L², and a wavy line representing a continuation of the chain. The chain L¹-L² is part of a larger macrocycle. The repeating unit, indicated by a subscript 'm' in brackets, consists of a nitrogen atom (N) bonded to R⁶, R⁵, R^{5'}, and a carbonyl group (C=O). This carbonyl group is further bonded to a nitrogen atom (N) which is bonded to R², R¹, R^{1'}, and another carbonyl group (C=O). The carbonyl group at the end of the repeating unit is bonded to the L¹ group, completing the macrocycle.

each of R¹, R³, and R⁵ is independently hydrogen or an optionally substituted group
om C₁₋₆ aliphatic, a 3-8 membered saturated or partially unsaturated monocyclic
c ring, phenyl, an 8-10 membered bicyclic aromatic carbocyclic ring, a 4-8 membered
or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms
ntly selected from nitrogen, oxygen, or sulfur, a 5-6 membered monocyclic
aromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or
an 8-10 membered bicyclic heteroaromatic ring having 1-5 heteroatoms independently
om nitrogen, oxygen, or sulfur; or:

R³ and R^{3'} are optionally taken together with their intervening carbon atom to form a 5-8 membered saturated or partially unsaturated spirocyclic carbocyclic ring or a 4-8 membered saturated or partially unsaturated spirocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur;

two R⁵ groups are optionally taken together with their intervening atoms to form a C₁₋₁₀ bivalent straight or branched saturated or unsaturated hydrocarbon chain wherein 1-3

methylene units of the chain are independently and optionally replaced with $-S-$, $-SS-$, $-N(R)-$, $-O-$, $-C(O)-$, $-OC(O)-$, $-C(O)O-$, $-C(O)N(R)-$, $-N(R)C(O)-$, $-S(O)-$, $-S(O)_2-$, or $-Cy^1-$, wherein each $-Cy^1-$ is independently a 5-6 membered heteroarylenyl with 1-4 heteroatoms independently selected from nitrogen, oxygen or sulfur;


each of R^1 , R^3 , and R^5 is independently hydrogen or C_{1-3} aliphatic;

each of R^2 , R^4 , and R^6 is independently hydrogen or C_{1-4} aliphatic, or:

R^2 and R^1 are optionally taken together with their intervening atoms to form a 4-8 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur;


R^4 and R^3 are optionally taken together with their intervening atoms to form a 4-8 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur; or

an R^6 group and its adjacent R^5 group are optionally taken together with their intervening atoms to form a 4-8 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur;



L^1 is a trivalent linker moiety that connects _____ and L^2 ;


L^2 is a covalent bond or a C_{1-10} bivalent straight or branched saturated or unsaturated hydrocarbon chain wherein 1-3 methylene units of the chain are independently and optionally replaced with $-S-$, $-N(R)-$, $-O-$, $-C(O)-$, $-OC(O)-$, $-C(O)O-$, $-C(O)N(R)-$, $-N(R)C(O)-$, $-$



$-S(O)-$, $-S(O)_2-$, _____, or $-Cy^1-$, wherein each $-Cy^1-$ is independently a 5-6 membered heteroarylenyl with 1-4 heteroatoms independently selected from nitrogen, oxygen or sulfur; and

each of m and n is independently 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10; or

(iii) the ABT-is a group of the formula



each of R⁷ is independently hydrogen or an optionally substituted group selected from C₁₋₆ aliphatic, a 3-8 membered saturated or partially unsaturated monocyclic carbocyclic ring, phenyl, an 8-10 membered bicyclic aromatic carbocyclic ring, a 4-8 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur, a 5-6 membered monocyclic heteroaromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or an 8-10 membered bicyclic heteroaromatic ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur; or:

an R⁷ group and the R^{7'} group attached to the same carbon atom are optionally taken together with their intervening carbon atom to form a 3-8 membered saturated or partially unsaturated spirocyclic carbocyclic ring or a 4-8 membered saturated or partially unsaturated spirocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur;

each of R^{7'} is independently hydrogen or C₁₋₃ aliphatic;

each of R⁸ is independently hydrogen, or C₁₋₄ aliphatic, or

an R⁸ group and its adjacent R⁷ group are optionally taken together with their intervening atoms to form a 4-8 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur;

R⁹ is hydrogen, C₁₋₃ aliphatic, or -C(O)C₁₋₃ aliphatic.

~~that can bind to one or more antibodies or fragments thereof, a target binding moiety that can bind to the cell, and optionally a linker moiety connecting the antibody binding moiety with the target binding moiety for use in a method of inducing cell death, inhibiting cell growth and/or reducing the number of cells in a system; wherein the method comprises administering to the system the antibody recruiting molecule (ARM) and optionally a plurality of natural killer cells;~~

so that the system is exposed to both and the number of cells in the system is reduced compared to absence of both the natural killer cells and the antibody recruiting molecule.

2. ~~A method for treating a condition, disorder or disease, comprising administering to a subject suffering therefrom:~~

~~a plurality of natural killer cells; and~~

~~An antibody recruiting molecule (ARM);~~

~~wherein the ARM comprises an antibody binding moiety that can bind to one or more antibodies or fragments thereof, a target binding moiety that can bind to the cancer cells, and optionally a linker moiety connecting the antibody binding moiety with the target binding moiety, for use in a method for treating a condition, disorder or disease the method, wherein the method comprises administering to a subject suffering from the condition, disorder, or disease, a plurality of natural killer cell and the antibody recruiting molecule (ARM).~~

3. ~~The antibody recruiting molecule (ARM), of claim 2, wherein the condition, disorder or disease is cancer.~~

4. ~~An antibody recruiting molecule (ARM);~~

~~wherein the ARM comprises an antibody binding moiety that can bind to one or more antibodies or fragments thereof, a target binding moiety that can bind to a target entity of the treatment, and optionally a linker moiety connecting the antibody binding moiety with the target binding moiety for use in a method of reducing side effects of a treatment using natural killer cells in a subject, the method comprising administering to the subject a plurality of natural killer cells and the antibody recruiting molecule (ARM).~~

5. ~~An antibody recruiting molecule (ARM);~~

~~wherein the ARM comprises an antibody binding moiety that can bind to one or more antibodies or fragments thereof, a target binding moiety that can bind to a target entity of the treatment, and optionally a linker moiety connecting the antibody binding moiety with the target binding moiety for use in a method of reducing toxicity of a treatment using natural killer cells in a subject, the method comprising administering to a subject a plurality of natural killer cells and~~

~~the antibody-recruiting molecule (ARM).~~

6. ~~2. The combination of claim 1, wherein ARM of any one of the preceding claims, for use in the method, the method comprising administering a plurality of natural killer cells to the subject, wherein the natural killer cells are memory-like natural killer cells.~~


7. ~~3. The combination of claim 1 or 2 ARM of any one of claims 1-5, for use in the method, the method comprising administering a plurality of natural killer cells to the subject, wherein the natural killer cells are cytokine-induced memory-like natural killer cells induced by IL-12, IL-15 and IL-18.~~

8. ~~The ARM of claim 6 or 7, for use in the method, the method comprising administering a plurality of natural killer cells to the subject, wherein the natural killer cells and the ARM are administered concurrently, optionally in one composition.~~

9. ~~The ARM of claim 6, for use in the method, the method comprising administering a plurality of natural killer cells to the subject wherein the natural killer cells are administered prior to or subsequently to the ARM.~~

10. ~~The ARM of claim 6, wherein the antibody binding moiety of the ARM is a universal antibody binding moiety.~~

11. ~~The ARM of claim 6, wherein the ARM is a compound of formula I:~~



I

~~or a pharmaceutically acceptable salt thereof, wherein:~~



~~ABT is an antibody binding moiety;~~

~~L is a bivalent linker moiety that connects ABT with TBT; and~~

~~TBT is a target binding moiety.~~

4. ~~The combination of any one of claims 1 to 3, wherein the ABT-L-ARM of claim 6, wherein the ARM is a compound-group of the formula II:~~

12.



II


~~or a pharmaceutically acceptable salt thereof, wherein:~~

~~each of R¹, R³ and R⁵ is independently hydrogen or an optionally substituted group selected from C₁₋₆-aliphatic, a 3-8 membered saturated or partially unsaturated monocyclic carbocyclic ring, phenyl, an 8-10 membered bicyclic aromatic carbocyclic ring, a 4-8 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur, a 5-6 membered monocyclic heteroaromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or an 8-10 membered bicyclic heteroaromatic ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur; or:~~


~~R¹ and R^{1'} are optionally taken together with their intervening carbon atom to form a 3-8 membered saturated or partially unsaturated spirocyclic carbocyclic ring or a 4-8 membered saturated or partially unsaturated spirocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur;~~

~~R³ and R^{3'} are optionally taken together with their intervening carbon atom to form a 3-~~


~~8-membered saturated or partially unsaturated spirocyclic carbocyclic ring or a 4-8 membered saturated or partially unsaturated spirocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur;~~
~~an R⁵-group and the R^{5'}-group attached to the same carbon atom are optionally taken together with their intervening carbon atom to form a 3-8 membered saturated or partially unsaturated spirocyclic carbocyclic ring or a 4-8 membered saturated or partially unsaturated spirocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur; or~~
~~two R⁵-groups are optionally taken together with their intervening atoms to form a C₁₋₁₀ bivalent straight or branched saturated or unsaturated hydrocarbon chain wherein 1-3 methylene units of the chain are independently and optionally replaced with —S—, —SS—, N(R)—, O—, C(O)—, OC(O)—, C(O)O—, C(O)N(R)—, N(R)C(O)—, S(O)—, —S(O)₂—, or —Cy¹—, wherein each —Cy¹— is independently a 5-6 membered heteroarylenyl with 1-4 heteroatoms independently selected from nitrogen, oxygen or sulfur;~~
~~each of R^{1'}, R^{3'} and R^{5'} is independently hydrogen or C₁₋₃ aliphatic;~~
~~each of R², R⁴ and R⁶ is independently hydrogen, or C₁₋₄ aliphatic, or:~~
~~R² and R¹ are optionally taken together with their intervening atoms to form a 4-8 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur;~~
~~R⁴ and R³ are optionally taken together with their intervening atoms to form a 4-8 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur; or~~
~~an R⁶-group and its adjacent R⁵-group are optionally taken together with their intervening atoms to form a 4-8 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur;~~



L^1 is a trivalent linker moiety that connects — and




L^2 is a covalent bond or a C_{1-10} bivalent straight or branched saturated or unsaturated hydrocarbon chain wherein 1-3 methylene units of the chain are independently and optionally replaced with S, N(R), O, C(O), OC(O), C(O)O, C(O)N(R), N(R)C(O), S(O),



TBT is a target binding moiety; and

each of m and n is independently 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10; or

wherein the ARM is a compound of formula **III**:



III

or a pharmaceutically acceptable salt thereof, wherein:

each of R^7 is independently hydrogen or an optionally substituted group selected from C_{1-6} aliphatic, a 3-8 membered saturated or partially unsaturated monocyclic carbocyclic ring, phenyl, an 8-10 membered bicyclic aromatic carbocyclic ring, a 4-8 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently

~~selected from nitrogen, oxygen, or sulfur, a 5-6 membered monocyclic heteroaromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or an 8-10 membered bicyclic heteroaromatic ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur; or:~~


~~an R⁷-group and the R^{7'}-group attached to the same carbon atom are optionally taken together with their intervening carbon atom to form a 3-8 membered saturated or partially unsaturated spirocyclic carbocyclic ring or a 4-8 membered saturated or partially unsaturated spirocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur;~~

~~each of R⁷² is independently hydrogen or C₁₋₃-aliphatic;~~

~~each of R⁸ is independently hydrogen, or C₁₋₄-aliphatic, or:~~

an R⁸-group and its adjacent R⁷-group are optionally taken together with their intervening atoms to form a 4-8 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur;

~~R⁹ is hydrogen, C₁₋₃-aliphatic, or C(O)C₁₋₃-aliphatic;~~




~~L³ is a bivalent linker moiety that connects~~

~~TBT is a target binding moiety; and~~

~~θ is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.~~

5. ~~The ARM combination of any one of of claim 6~~claims 1 to 3, wherein the ~~ARM-ABT~~ is a ~~compound having the structure~~group of the formula



I-a

or a salt thereof, wherein:

each Xaa is independently an amino acid residue;

t is 0-50;

z is 1-50;

L is a linker moiety;

TBT is a target binding moiety;

each R^e is independently -L^a-R';

each of a and b is independently 1-200;

each L^a is independently a covalent bond, or an optionally substituted bivalent group selected C₁-C₂₀ aliphatic or C₁-C₂₀ heteroaliphatic having 1-5 heteroatoms, wherein one or more methylene units of the group are optionally and independently replaced with -C(R')₂-, -Cy-, =O-, =S-, =S-S-, -N(R')-, -C(O)-, -C(S)-, -C(NR')-, -C(O)N(R')-, -N(R')C(O)N(R')-, =N(R')C(O)O-, -S(O)-, -S(O)₂-, -S(O)₂N(R')-, -C(O)S-, or -C(O)O-;

each -Cy- is independently an optionally substituted bivalent group selected from a C₃₋₂₀ cycloaliphatic ring, a C₆₋₂₀ aryl ring, a 5-20 membered heteroaryl ring having 1-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus and silicon, and a 3-20 membered heterocyclyl ring having 1-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus and silicon;

each R' is independently -R, -C(O)R, -CO₂R, or -SO₂R;

each R is independently -H, or an optionally substituted group selected from C₁₋₃₀ aliphatic, C₁₋₃₀ heteroaliphatic having 1-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus and silicon, C₆₋₃₀ aryl, C₆₋₃₀ arylaliphatic, C₆₋₃₀ arylheteroaliphatic having 1-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus and silicon, 5-30 membered heteroaryl having 1-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus and silicon, and 3-30 membered heterocyclyl having 1-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus and silicon, or


two R-groups are optionally and independently taken together to form a covalent bond,

or:

two or more R-groups on the same atom are optionally and independently taken together with the atom to form an optionally substituted, 3-30 membered, monocyclic, bicyclic or

polycyclic ring having, in addition to the atom, 0-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus and silicon; or

two or more R groups on two or more atoms are optionally and independently taken together with their intervening atoms to form an optionally substituted, 3-30 membered, monocyclic, bicyclic or polycyclic ring having, in addition to the intervening atoms, 0-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus and silicon; or wherein the ARM is a compound having the structure of formula **I-b**:



I-b

or a salt thereof, wherein:

each Xaa is independently an amino acid residue;

each z is independently 1-50;

each L is independently a linker moiety;

TBT is a target binding moiety,

each R^c is independently $-L^a-R'$;

each of a1 and a2 is independently 0-200, wherein at least one of a1 and a2 is not 0;

b is 1-200;

each L^a is independently a covalent bond, or an optionally substituted bivalent group selected C_1 - C_{20} aliphatic or C_1 - C_{20} heteroaliphatic having 1-5 heteroatoms, wherein one or more methylene units of the group are optionally and independently replaced with $-C(R')_2-$, $-Cy-$, $-O-$, $-S-$, $-S-S-$, $-N(R')-$, $-C(O)-$, $-C(S)-$, $-C(NR')-$, $-C(O)N(R')-$, $-N(R')C(O)N(R')-$, $-N(R')C(O)O-$, $-S(O)-$, $-S(O)_2-$, $-S(O)_2N(R')-$, $-C(O)S-$, or $-C(O)O-$;

each $-Cy-$ is independently an optionally substituted bivalent group selected from a C_{3-20} cycloaliphatic ring, a C_{6-20} aryl ring, a 5-20 membered heteroaryl ring having 1-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus and silicon, and a 3-20 membered heterocyclyl ring having 1-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus and silicon;

each R' is independently $-R$, $-C(O)R$, $-CO_2R$, or $-SO_2R$;

each R is independently $-H$, or an optionally substituted group selected from C_{1-30} aliphatic, C_{1-30} heteroaliphatic having 1-10 heteroatoms independently selected from oxygen,

~~nitrogen, sulfur, phosphorus and silicon, C₆₋₃₀-aryl, C₆₋₃₀-arylaliphatic, C₆₋₃₀-arylheteroaliphatic having 1-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus and silicon, 5-30 membered heteroaryl having 1-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus and silicon, and 3-30 membered heterocyclyl having 1-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus and silicon, or two R groups are optionally and independently taken together to form a covalent bond, or:~~

~~two or more R groups on the same atom are optionally and independently taken together with the atom to form an optionally substituted, 3-30 membered, monocyclic, bicyclic or polycyclic ring having, in addition to the atom, 0-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus and silicon; or~~

~~two or more R groups on two or more atoms are optionally and independently taken together with their intervening atoms to form an optionally substituted, 3-30 membered, monocyclic, bicyclic or polycyclic ring having, in addition to the intervening atoms, 0-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus and silicon.~~

~~14. The ARM of claim 6, wherein the ARM is administered with an antibody or a fragment thereof.~~

15. 6. The combination of ARM of claim 1, wherein the antibody binding moiety (ABT) is or comprises a peptide unit that is or comprises DCAWHLGELVWCT, wherein the two cysteine residues optionally form a disulfide bond.

16. 7. The combination of ARM of claim 16, wherein the antibody binding moiety (ABT) is or comprises a peptide unit that is or comprises CDCAWHLGELVWCTC, wherein the first and the last cysteines, and the two cysteines in the middle of the sequence, each independently and optionally form a disulfide bond.

17. ~~A combination comprising:~~
~~a plurality of natural killer cells; and~~
~~an antibody recruiting molecule (ARM), wherein:~~

~~the ARM comprises an antibody binding moiety that can bind to one or more antibodies, or fragments thereof, a target binding moiety that can bind to a target entity, and optionally a linker moiety connecting the antibody binding moiety with the target binding moiety.~~


~~18. The combination of claim 17, wherein the natural killer cells are natural killer cells of any one of claims 1-16, and/or the ARM is an ARM of any one of claims 1-16.~~

~~19. A composition comprising:
a plurality of natural killer cells; and
an antibody recruiting molecule (ARM), wherein:
the ARM comprises an antibody binding moiety that can bind to one or more antibodies, or fragments thereof, a target binding moiety that can bind to a target entity, and optionally a linker moiety connecting the antibody binding moiety with the target binding moiety.~~


~~20. The composition of claim 19, wherein the natural killer cells are natural killer cells of any one of claims 1-5, and/or the ARM is an ARM of any one of claims 1-5.~~

~~21. 8. The composition combination of any one of claims 19 or 20 to 7, wherein the composition comprises an antibody or a fragment thereof.~~


~~9. The anti-body recruiting molecule (ARM) or combination of any one of Embodiments 1-103 or Example disclosed herein combination of claim 1, wherein the ABT is or comprises any one of the following:-~~




A-10




A-11




A-12




A-13




A-14







A-15




A-16




A-17



	
<p><u>A-18</u></p>	<p><u>A-19</u></p>
	
<p><u>A-20</u></p>	<p><u>A-21</u></p>




A-22




A-23

A-24


A-25




[A-26](#)




[A-27](#)




[A-28](#)





[A-29](#)




A-30




A-31


A-32A-33




A-34




A-35




A-36




A-37




A-38




A-39




A-40




A-41




A-42







A-44



A-43



A-45

	
<p><u>A-46</u></p>	<p><u>A-47</u></p>
	
<p><u>A-48</u></p>	<p><u>A-49</u></p>

7

22. _____

23. 10. _____ An anti-body recruiting molecule (ARM) of ~~formula I~~ the formula:

each R is independently –H, or an optionally substituted group selected from C₁₋₃₀ aliphatic, C₁₋₃₀ heteroaliphatic having 1-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus and silicon, C₆₋₃₀ aryl, C₆₋₃₀ arylaliphatic, C₆₋₃₀ arylheteroaliphatic having 1-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus and silicon, 5-30 membered heteroaryl having 1-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus and silicon, and 3-30 membered heterocyclyl having 1-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus and silicon, or two R groups are optionally and independently taken together to form a covalent bond, or:

two or more R groups on the same atom are optionally and independently taken together with the atom to form an optionally substituted, 3-30 membered, monocyclic, bicyclic or polycyclic ring having, in addition to the atom, 0-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus and silicon; or

two or more R groups on two or more atoms are optionally and independently taken together with their intervening atoms to form an optionally substituted, 3-30 membered, monocyclic, bicyclic or polycyclic ring having, in addition to the intervening atoms, 0-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus and silicon.

~~24. —The ARM of claim 23, wherein a is 1 and b is 1.~~

~~11. 25. —The ARM of claim 23 or 24~~10, wherein –(Xaa)_z– is or comprises –X³X⁴X⁵X⁶X⁷X⁸X⁹X¹⁰X¹¹X¹²–, wherein:

each of X³, X⁴, X⁵, X⁶, X⁷, X⁸, X⁹, X¹⁰, X¹¹, and X¹² is independently an amino acid residue;

X⁶ is Xaa^A or Xaa^P;

X⁹ is Xaa^N; and

X¹² is Xaa^A or Xaa^P,

wherein each Xaa^A is independently an amino acid residue whose side chain comprises an aromatic group, each Xaa^P is independently an amino acid residue whose side chain comprises a positively charged side chain, and each Xaa^N is independently an amino acid residue whose side chain comprises a negatively charged side chain.

~~12.~~ 26.—The ARM of claim 10 or 11~~23 or 24~~, wherein $-(Xaa)_z-$ is or comprises $-X^3X^4X^5X^6X^7X^8X^9X^{10}X^{11}X^{12}-$, wherein:

at least two amino acid residues are connected through one or more linkages L^b ;

L^b is an optionally substituted bivalent group selected C_1 - C_{20} aliphatic or C_1 - C_{20} heteroaliphatic having 1-5 heteroatoms, wherein one or more methylene units of the group are optionally and independently replaced with $-C(R')_2-$, $-Cy-$, $-O-$, $-S-$, $-S-S-$, $-N(R')-$, $-C(O)-$, $-C(S)-$, $-C(NR')-$, $-C(O)N(R')-$, $-N(R')C(O)N(R')-$, $-N(R')C(O)O-$, $-S(O)-$, $-S(O)_2-$, $-S(O)_2N(R')-$, $-C(O)S-$, or $-C(O)O-$, wherein L^b is bonded to a backbone atom of one amino acid residue and a backbone atom of another amino acid residue, and comprises no backbone atoms;

X^6 is Xaa^A or Xaa^P ;

X^9 is Xaa^N ;





X^{12} is Xaa^A or Xaa^P ; and





wherein each Xaa^A is independently an amino acid residue whose side chain comprises an aromatic group, each Xaa^P is independently an amino acid residue whose side chain comprises a positively charged side chain, and each Xaa^N is independently an amino acid residue whose side chain comprises a negatively charged side chain.





1327. The ARM of any one of claims ~~23 to 26~~10 to 12, wherein each of X^4 , X^7 , and X^{11} is independently an amino acid residue with a hydrophobic side chain (“hydrophobic amino acid residue”, Xaa^H).





1428. The ARM of claim ~~23 or 24~~10 or 11, wherein $(Xaa)_z$ is or comprises DCAWHLGELVWCT, wherein the two cysteine residues optionally form a disulfide bond.





1529. An anti-body recruiting molecule (ARM), of claim 10 or 11~~23 or 24~~, wherein $(Xaa)_z$ is or comprises any one of





	
A-10	A-11
	
A-12	A-13





	
A-14	A-15
	
A-16	A-17





	
A-18	A-19
	
A-20	A-21





	
A-22	A-23
	
A-24	A-25





	
A-26	A-27
	
A-28	A-29

	
A-30	A-31
	
A-32	A-33


	
A-34	A-35
	
A-36	A-37

	
A-38	A-39
	
A-40	A-41


	
A-42	A-43
	
A-44	A-45

	
A-46	A-47
	 <p>or</p>
A-48	A-49



1630. An anti-body recruiting molecule (ARM), selected from:







(I-9);






(I-10);
















(I-19);



(I-20);



















(I-31);




(I-32);



or



1731.—An anti-body recruiting molecule (ARM), of the formula:



18. A combination of any one of claims 1 to 10 or an ARM of any one of claims 11 to 17 for use in a method of treating cancer.

19. The combination or ARM of claim 18, for use in a method of treating prostate cancer, metastatic prostate cancer, stomach cancer, colon uterine cancer, ovarian cancer, testicular cancer, bladder cancer, renal cancer, brain/CNS cancer, head and neck cancer, throat cancer, Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, leukemia, melanoma, non-melanoma skin cancer, acute lymphocytic leukemia, acute myelogenous leukemia, Ewing's sarcoma, small cell lung cancer, choriocarcinoma, rhabdomyosarcoma, Wilms' tumor, neuroblastoma, hairy cell leukemia, mouth/pharynx cancer, esophageal cancer, larynx cancer, kidney cancer, or lymphoma.

20. The combination or ARM of claim 18, for use in a method of treating leukemia, lymphoma, or melanoma.